Pharma traded defensively green as the chip rout raged elsewhere — Eli Lilly +7.1% on a Medicare GLP-1 access program and an EU cancer-drug nod, while Corning gave back 3.1%.

Eli Lilly (LLY) led the pharma basket, up 7.1% to $1,208.12 — its best single session in months and a notable move for a typically low-volatility megacap. Two catalysts drove it: Medicare unveiled a GLP-1 Bridge program, starting July 1, that opens access to Lilly's Zepbound and oral Foundayo at a ~$50 monthly copay for eligible patients; and the EMA's CHMP backed Jaypirca for chronic lymphocytic leukemia, paving the way for EU approval within months. Through this map, the Medicare news lands on the fill-finish chokepoint: a structural expansion in insured GLP-1 volume tightens demand for sterile fill-finish and parenteral capacity, the most stretched link in the injectables supply chain. The move was an access-driven volume signal, not a pricing one.

Corning (GLW) was the basket's worst quotable name, down 3.1% to $221.05 — but the move was a give-back of the prior session's ~10.8% rally, not a pharma story. Corning maps here to the pharma-glass chokepoint via its Valor borosilicate vials, yet Friday's pullback was driven by its far larger optical and solar businesses: the AI-optical demand that powered Thursday's surge cooled with the broader chip tape, and management's flagged solar-ramp expense overhang resurfaced. The pharma-glass thesis — domestic, contamination-resistant vial capacity for the injectables boom — is intact; the stock simply trades on its optical multiple, and that multiple wobbled.

Pharma was a relative haven as capital rotated into defensives. The GLP-1 and peptide complex firmed on the Medicare news — Novo Nordisk (NVO +0.9%), Bachem (BCHMY +4.0%, peptides), Amphastar (AMPH +3.5%) and Baxter (BAX +2.3%, sterile injectables). The bioprocessing and tools chokepoints were quietly green: Thermo Fisher (TMO +1.4%), Danaher (DHR +1.5%), Repligen (RGEN +1.2%), West Pharmaceutical (WST +1.2%), Charles River (CRL +1.4%) and Mettler-Toledo (MTD +1.6%). Many smaller packaging and API ADRs were unchanged on the day. After a brutal week for technology, the sterile-supply and CDMO chokepoints offered exactly the low-beta exposure that defensive rotation seeks.

The calendar is heavy and policy-charged. The Medicare GLP-1 Bridge program goes live July 1, and Section 232 pharmaceutical tariffs — 100% on patented pharma and APIs — are set to take effect July 31, the central catalyst for the api-reshoring chokepoint. Earnings then arrive: Thermo Fisher (July 22), the FDA's classification decision on Novo's Bloomington fill-finish site (July 23), West Pharmaceutical and Sartorius (July 23), Corning (July 28) and Novo Nordisk's H1 (Aug 5). The fill-finish and CDMO chokepoints will be read hardest against the GLP-1 volume ramp.